TP53 and familial pancreatic carcinoma: A Phase II clinical trial (NCT02340117) study of combined targeted P53 gene therapy (SGT-53) with Gemcitabine/Nab-Paclitaxel for the treatment of metastatic pancreatic cancer is currently ongoing (Leung et al., 2021).